Malignant hyperthermia: current strategies for effective diagnosis and management

Bibliography

• Wappler F. Malignant hyperthermia. Eur J Anaesthesiol 2001;18:632-52
   PubMed Web of Science ®Google Scholar
• Dexter F, Epstein RH, Wachtel RE, Rosenberg H. Estimate of the relative risk of succinylcholine for triggering malignant hyperthermia. Anesth Analg 2013;116:118-22
   PubMedGoogle Scholar
• Riazi S, Larach MG, Hu C, et al. Malignant hyperthermia in Canada: characteristics of index anesthetics in 129 malignant hyperthermia susceptible probands. Anesth Analg 2013. [Epub ahead of print]
   Google Scholar
• Wappler F, Fiege M, Steinfath M, et al. Evidence for susceptibility to malignant hyperthermia in patients with stress-induced rhabdomyolysis. Anesthesiology 2001;94:95-100
   PubMedGoogle Scholar
• Capacchione JF, Muldoon SM. The relationship between exertional heat illness, exertional rhabdomyolysis, and malignant hyperthermia. Anesth Analg 2009;109:1065-9
   PubMedGoogle Scholar
• Groom L, Muldoon SM, Tang ZZ, et al. Identical de novo mutation in the type 1 ryanodine receptor gene associated with fatal, stress-induced malignant hyperthermia in two unrelated families. Anesthesiology 2011;115:938-45
   PubMedGoogle Scholar
• Lavezzi WA, Capacchione JF, Muldoon SM, et al. Death in the emergency department: an unrecognized awake malignant hyperthermia-like reation in a six-year-old. Anesth Analg 2013;116:420-3
   PubMedGoogle Scholar
• Pessah IN, Lynch C, Gronert GA. Complex pharmacology of malignant hyperthermia. Anesthesiology 1996;84:1275-9
   PubMedGoogle Scholar
• Duke AM, Hopkins PM, Calaghan SC, et al. Store-operated Ca2+ entry in malignant hyperthermia-susceptible human skeletal muscle. J Biol Chem 2010;285:25645-53
   PubMedGoogle Scholar
• Ducreux S, Zorzato F, Müller C, et al. Effect of ryanodine receptor mutations on interleukin-6 release and intracellular calcium homeostasis in human myotubes from malignant hyperthermia-susceptible individuals and patients affected by central core disease. J Biol Chem 2004;279:43838-46
   PubMedGoogle Scholar
• Rosenberg H, Davis M, James D, et al. Malignant hyperthermia. Orphanet J Rare Dis 2007;2:21
   PubMed Web of Science ®Google Scholar
• Rosero EB, Adesanya AO, Timaran CH, Joshi GP. Trends and outcomes of malignant hyperthermia in the United States. 2000 to 2005. Anesthesiology 2009;110:89-94
   PubMed Web of Science ®Google Scholar
• Gonsalves SG, Ng D, Johnston JJ, et al. Using exome data to identify malignant hyperthermia susceptibility mutations. Anesthesiology 2013;119:1043-53
   PubMed Web of Science ®Google Scholar
• Glahn K, Ellis FR, Halsall PJ, et al. Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group. Br J Anaesth 2010;105:417-20
   PubMed Web of Science ®Google Scholar
• Mellin-Olsen J, Staender S, Whitaker DK, Smith AF. The Helsinki Declaration on Patient Safety in Anaesthesiology. Eur J Anaesthesiol 2010;2:592-7
   Google Scholar
• Available from: http://www.MHAUS.org
   Google Scholar
• Reber A, Schumacher P, Urwyler A. Effects of three different types of management on the elimination kinetics of volatile anaesthetics. Anaesthesia 1993;48:862-5
   PubMedGoogle Scholar
• Newmark JL, Voelkel M, Brandom BW, Wu J. Delayed onset of malignant hyperthermia without creatine kinase elevation in a geriatric, ryanodine receptor type 1 gene compound heterozygous patient. Anesthesiology 2007;107:350-3
   PubMedGoogle Scholar
• Krause T, Gerbershagen MU, Fiege M, et al. Dantrolene – a review of its pharmacology, therapeutic use and new developments. Anaesthesia 2004;59:364-73
   PubMed Web of Science ®Google Scholar
• Nelson TE, Lin M, Zapata-Sudo G, Takashi-Sudo R. Dantrolene sodium can increase or attenuate activity of skeletal muscle ryanodine receptor calcium release channel. Anesthesiology 1996;84:1368-79
   PubMedGoogle Scholar
• Wang R, Zhong X, Meng X, et al. Localization of the dantrolene-binding sequence near the FK506-binding protein-binding site in the three-dimensional structure of the ryanodine receptor. J Biol Chem 2011;286:12202-12
   PubMedGoogle Scholar
• Eltit JM, Ding X, Pessah IN, et al. Nonspecific sarcolemmal cation channels are critical for the pathogenesis of malignant hyperthermia. FASEB J 2013;27:991-100
   PubMedGoogle Scholar
• Treves S, Jungbluth H, Muntoni F, Zorzato F. Congenital muscle disorders with cores: the ryanodine receptor calium channel paradigm. Curr Opin Pharmacol 2008;8:319-28
   PubMedGoogle Scholar
• Klingler W, Rueffert H, Lehmann-Horn F, et al. Core myopathies and risk of malignant hyperthermia. Anesth Analg 2009;109:1167-73
   Google Scholar
• Kraeva N, Zvaritch E, Rossi AE, et al. Novel excitation-contraction uncoupled RYR1 mutations in patients with central core disease. Neuromuscul Disord 2013;23:120-32
   PubMedGoogle Scholar
• Parness J, Bandschapp O, Girard T. The myotonias and susceptibility to malignant hyperthermia. Anesth Analg 2009;109:1054-64
   PubMedGoogle Scholar
• Gurnaney H, Brown A, Litman RS. Malignant hyperthermia and muscular dystrophies. Anesth Analg 2009;109:1043-8
   PubMed Web of Science ®Google Scholar
• Larsen UT, Juhl B, Hein-Sorensen O, de Fine Olivarius B. Complications during anaesthesia in patients with Duchenne's muscular dystrophy (a retrospective study). Can J Anaesth 1989;36:418-22
   PubMedGoogle Scholar
• Segura LG, Lorenz JD, Weingarten TN, et al. Anesthesia and Duchenne or Becker muscular dystrophy: review of 117 anesthetic exposures. Paediatr Anaesth 2013;23:855-64
   PubMed Web of Science ®Google Scholar
• Wappler F. Anaesthesia for patients with history of malignant hyperthermia. Curr Opin Anaesthesiol 2010;23:417-22
   PubMedGoogle Scholar
• De Hert SG, Imberger G, Carlisle J, et al. Preoperative evaluation of the adult patient undergoing non-cardiac surgery: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 2011;28:684-722
   PubMedGoogle Scholar
• Benca J, Hogan K. Malignant hyperthermia, coexisting disorders, and enzymopathies: risks and management options. Anesth Analg 2009;109:1049-53
   Google Scholar
• Available from: http://www.EMHG.org
   Google Scholar
• Hopkins PM. Malignant hyperthermia: advances in clinical management and diagnosis. Br J Anaesth 2000;85:118-28
   PubMed Web of Science ®Google Scholar
• Sufit RL, Kreul JF, Bellay YM, et al. Doxacurium and Mivacurium do not trigger malignant hyperthermia in swine. Anesth Analg 1990;71:285-7
   PubMedGoogle Scholar
• Williams C, Dozier S, Ilias W, Fulfer R. Malignant hyperthermia in swine: a study of atracurium in MH-susceptible swine. Anaesthesiol Reanim 1994;19:23-5
   PubMedGoogle Scholar
• Murray C, Sasaki SS, Berg D. Local anesthesia and malignant hyperthermia. Dermatol Surg 1999;25:626-30
   PubMedGoogle Scholar
• Froeba G, Mary T, Pazhur J, et al. Xenon does not trigger malignant hyperthermia in susceptible swine. Anesthesiology 1999;91:1047-52
   PubMed Web of Science ®Google Scholar
• Pollock N, Langton E, Stowell K, et al. Safe duration of postoperative monitoring for malignant hyperthermia susceptible patients. Anaesth Intensive Care 2004;32:502-9
   PubMedGoogle Scholar
• Pollock N, Langton E, MacDonnell N, et al. Malignant hyperthermia and day stay surgery. Anaesth Intensive Care 2006;34:40-5
   PubMedGoogle Scholar
• Kalow W, Britt BA, Terraeu ME, Haist C. Metabolic error of muscle metabolism after recovery from malignant hyperthermia. Lancet 1970;2:895-8
   PubMed Web of Science ®Google Scholar
• Ellis FR, Harriman DGF, Keaney NP, et al. Halothane-induced muscle contracture as a cause of hyperpyrexia. Br J Anaesth 1971;43:721-2
   PubMed Web of Science ®Google Scholar
• European Malignant Hyperpyrexia Group. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. Br J Anaesth 1984;56:1267-9
   PubMed Web of Science ®Google Scholar
• Larach MG. North American Malignant Hyperthermia Group. Standardization of the caffeine halothane muscle contracture test. Anesth Analg 1989;69:511-15
   PubMed Web of Science ®Google Scholar
• Ørding H, Brancadoro V, Cozzolino S, et al. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and un-related low-risk subjects. Acta Anaesthesiol Scand 1997;41:955-66
   PubMedGoogle Scholar
• Allen GC, Larach MH, Kunselman AR. The sensitivity and specificity of the caffeine halothane contracture test: a report from the North American Malignant Hyperthermia Registry. Anesthesiology 1998;88:579-88
   PubMed Web of Science ®Google Scholar
• Mickelson JR, Gallant EM, Litterer LA, et al. Abnormal sarcoplasmic reticulum ryanodine receptor in malignant hyperthermia. J Biol Chem 1988;263:9310-15
   PubMed Web of Science ®Google Scholar
• Hopkins PM, Ellis FR, Halsall PJ. Ryanodine contracture: a potentially specific in vitro diagnostic test for malignant hyperthermia. Br J Anaesth 1991;66:611-13
   PubMedGoogle Scholar
• Wappler F, Roewer N, Lenzen C, et al. High-purity ryanodine and 9,21-dehydroryanodine for in vitro diagnosis of malignant hyperthermia in man. Br J Anaesth 1994;72:240-2
   PubMedGoogle Scholar
• Wappler F, Roewer N, Köchling A, et al. In vitro diagnosis of malignant hyperthermia susceptibility with ryanodine-induced contractures in human skeletal muscles. Anesth Analg 1996;82:1230-6
   PubMedGoogle Scholar
• Hartung E, Koob M, Anetseder M, et al. Malignant hyperthermia (MH) diagnostics: a comparison between the halothane-caffeine- and the ryanodine-contracture-test results in MH susceptible, normal and control muscle. Acta Anaesthesiol Scand 1996;40:437-44
   PubMedGoogle Scholar
• Hopkins PM, Hartung E, Wappler F. The European Malignant Hyperthermia Group. Multi centre evaluation of ryanodine contracture testing in malignant hyperthermia. Br J Anaesth 1998;80:389-94
   PubMedGoogle Scholar
• Zorzato F, Scutari E, Tegazzin V, et al. Chlorocresol: An activator of ryanodine receptor-mediated Ca2+ release. Mol Pharmacol 1993;44:1192-201
   PubMedGoogle Scholar
• Herrmann-Frank A, Richter M, Sarközi S, et al. 4-chloro-m-cresol, a potent and specific activator of the skeletal muscle ryanodine receptor. Biochem Biophys Acta 1996;1289:31-40
   PubMed Web of Science ®Google Scholar
• Tegazzin V, Scutari E, Treves S, Zorzato F. Chlorocresol, an additive to commercial succinylcholine, induces contracture of human malignant hyperthermia-susceptible muscle via activation of the ryanodine receptor Ca2+ channel. Anesthesiology 1996;84:380-5
   Google Scholar
• Baur C, Bellon L, Felleiter P, et al. A multicenter study of 4-chloro-m-cresol for diagnosing malignant hyperthermia susceptibility. Anesth Analg 2000;90:200-5
   PubMedGoogle Scholar
• Wappler F, Anetseder M, Baur CP, et al. Multicenter evaluation of in vitro contracture testing with bolus administration of 4-chloro-m-cresol for diagnosis of malignant hyperthermia susceptibility. Eur J Anaesthesiol 2003;20:528-36
   PubMedGoogle Scholar
• Snoeck MMJ, Gielen MJM, Tangerman A, van Egmond J. Contractures in skeletal muscle of malignant hyperthermia susceptible patients after in vitro exposure to sevoflurane. Acta Anaesthesiol Scand 2000;44:334-7
   PubMedGoogle Scholar
• Metterlein T, Hartung E, Schuster F, et al. Sevoflurane as a potential replacement for halothane in diagnostic testing for malignant hyperthermia susceptibility: results of a preliminary study. Minerva Anestesiol 2011;77:768-73
   PubMedGoogle Scholar
• Foster PS, Gesini E, Denborough MA. Inositol 1,4,5-trisphosphate metabolism in red blood cells from individuals susceptible to malignant hyperpyrexia. Lancet 1993;342:986-7
   PubMedGoogle Scholar
• Solomons CC, Masson NC. Platelet model for halothane-induced effects on nucleotide metabolism applied to malignant hyperthermia. Acta Anaesthesiol Scand 1984;28:185-90
   PubMedGoogle Scholar
• Martens U, Krause T, Scholz J, et al. Inositol 1,4,5-trisphosphate synthesis in mononuclear white blood cells of malignant hyperthermia-susceptible and – normal human individuaks following in vitro exposure to halothane, caffeine and ryanodine. Eur J Anaesthesiol 2000;17:364-72
   PubMedGoogle Scholar
• Scholz J, Troll U, Schulte am Esch J, et al. Inositol-1,4,5-trisphophate and malignant hyperthermia. Lancet 1991;337:1361
   PubMedGoogle Scholar
• Wappler F, Scholz J, Köchling A, et al. Inositol 1,4,5-trisphosphate in blood and skeletal muscle in human malignant hyperthermia. Br J Anaesth 1997;78:541-7
   PubMedGoogle Scholar
• Sei Y, Brandom BW, Bina S, et al. Patients with malignant hyperthermia demonstrate an altered calcium control mechanism in B-lymphocytes. Anesthesiology 2002;97:1052-8
   PubMed Web of Science ®Google Scholar
• McKinney LC, Butler T, Mullen SP, Klein MG. Characterization of ryanodine receptor-mediated calcium release in human B cells: relevance to diagnostic testing for malignant hyperthermia. Anesthesiology 2006;104:1191-201
   PubMedGoogle Scholar
• Bina S, Cappachione J, Muldoon S, et al. Lymphocyte-based determination of susceptibility to malignant hyperthermia: a pilot study in swine. Anesthesiology 2010;113:917-24
   PubMedGoogle Scholar
• Anetseder M, Hager M, Müller CR, Roewer N. Diagnosis of susceptibility to malignant hyperthermia by use of a metabolic test. Lancet 2002;359:1579-80
   PubMed Web of Science ®Google Scholar
• Bina S, Cowan G, Karaian J, et al. Effects of caffeine, halothane, and 4-chloro-m-cresol on skeletal muscle lactate and pyruvate in malignant hyperthermia-susceptible and normal swine assessed by microdialysis. Anesthesiology 2006;104:90-100
   PubMed Web of Science ®Google Scholar
• Schuster F, Metterlein T, Negele S, et al. Intramuscular injection of sevoflurane detects malignant hyperthermia predisposition in susceptible pigs. Anesthesiology 2007;107:616-20
   PubMed Web of Science ®Google Scholar
• Schuster F, Metterlein T, Negele S, et al. An in-vivo metabolic test for detecting malignant hyperthermia susceptibility in humans: a pilot study. Anesth Analg 2008;107:909-14
   PubMed Web of Science ®Google Scholar
• Metterlein T, Schuster F, Kranke P, et al. Intramuscular injection of malignant hyperthermia trigger agents induces hypermetabolism in susceptible and nonsusceptible individuals. Eur J Anaesthesiol 2010;27:77-82
   PubMed Web of Science ®Google Scholar
• Denborough MA, Lovell RRH. Anaesthetic deaths in a family. Letter. Lancet 1960;2:45
   Web of Science ®Google Scholar
• Andresen E, Jensen P. Close linkage established between the HAL locus for halothane sensitivity and the PHI (phosphohexose isomerase) locus in pigs of the Danish landrace breed. Nord Vet Med 1977;29:502-4
   PubMedGoogle Scholar
• Harbitz I, Chowdhary B, Thomsen PD, et al. Assignment of the porcine calcium release channel gene, a candidate for the malignant hyperthermia locus, to the 6p11-q21 segment of chromosome 6. Genomics 1990;8:243-8
   PubMedGoogle Scholar
• Zorzato F, Fujii J, Otsu K, et al. Molecular cloning of cDNA encoding human and rabbit forms of the Ca2+ release channel (ryanodine receptor) of skeletal muscle sarcoplasmic reticulum. J Biol Chem 1990;265:2244-56
   PubMed Web of Science ®Google Scholar
• MacLennan DH, Duff C, Zorzato F, et al. Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature 1990;343:559-61
   PubMed Web of Science ®Google Scholar
• McCarthy TV, Quane KA, Lynch PJ. Ryanodine receptor mutations in malignant hyperthermia and central core disease. Hum Mutat 2000;15:410-17
   PubMed Web of Science ®Google Scholar
• Sato K, Pollock N Stowell KM. Functional studies of RYR1 mutations in the skeletal muscle ryanodine receptor using human RYR1 complementary DNA. Anesthesiology 2010;112:1350-4
   PubMedGoogle Scholar
• Kraeva N, Riazi S, Loke J, et al. Ryanodine receptor type 1 gene mutations found in the Canadian malignant hyperthermia population. Can J Anaesth 2011;58:504-13
   PubMed Web of Science ®Google Scholar
• Urwyler A, Deufel T, McCarthy T, et al. Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia. Br J Anaesth 2001;86:283-7
   PubMedGoogle Scholar
• Mezin P, Payen JF, Bosson JL, et al. Histological support for the difference between malignant hyperthermia susceptible (MHS), equivocal (MHE) and negative (MHN) muscle biopsies. Br J Anaesth 1997;79:327-31
   PubMedGoogle Scholar
• Von Breunig F, Wappler F, Hagel C, et al. Histomorphologic examination of skeletal muscle preparations does not differentiate between malignant hyperthermia – susceptible and – normal patients. Anesthesiology 2004;100:789-94
   PubMedGoogle Scholar
• Orlov D, Keith J, Rosen D, et al. Analysis of histomorphology in malignant hyperthermia-susceptible patients. Can J Anaesth 2013;60:982-9
   PubMedGoogle Scholar
• Rosenberg H, Fletcher JE. An update on the malignant hyperthermia syndrome. Ann Acad Med Singapore 1994;23:84-97
   PubMedGoogle Scholar
• Brandom BW, Larach MG, Chen MSA, Young MC. Complications associated with the administration of dantrolene 1987 to 2006: a report from the North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United States. Anesth Analg 2011;112:1115-23
   PubMed Web of Science ®Google Scholar
• Kugler Y, Russell WJ. Speeding dantrolene preparation for treating malignant hyperthermia. Anaesth Intensive Care 2011;39:84-8
   PubMedGoogle Scholar
• Baker KR, Landriscina D, Kartchner H, Mirkes DM. The icarus effect: the influence of diluent warming on dantrolene sodium mixing time. AANA J 2007;75:101-6
   PubMedGoogle Scholar
• Schütte JK, Becker S, Burmester S, et al. Comparison of the therapeutic effectiveness of a dantrolene sodium solution and a novel nanocrystalline suspension of dantrolene sodium in malignant hyperthermia normal and susceptible pigs. Eur J Anaesthesiol 2011;28:256-64
   PubMed Web of Science ®Google Scholar
• Burkman JM, Posner KL, Domino KB. Analysis of the clinical variables associated with recrudescence after malignant hyperthermia reactions. Anesthesiology 2007;106:901-6
   PubMed Web of Science ®Google Scholar
• Petroz GC, Lerman J. Preparation of the Siemens KION anesthetic machine for patients susceptible to malignant hyperthermia. Anesthesiology 2002;96:941-6
   PubMedGoogle Scholar
• Prinzhausen H, Crawford MW, O´Rourke J. Preparation of the Dräger Primus anesthetic machine for malignant-hyperthermia susceptible patients. Can J Anaesth 2006;53:885-90
   PubMedGoogle Scholar
• Crawford MW, Prinzhausen H, Petroz GC. Accelerating the washout of inhalational anesthetics from the Dräger Primus anesthetic workstation. Anesthesiology 2007;106:289-94
   PubMedGoogle Scholar
• Whitty RJ, Wong GK, Petroz GC, et al. Preparation of the Dräger Fabius GS™ workstation for malignant-hyperthermia susceptible patients. Can J Anaesth 2009;56:497-501
   PubMedGoogle Scholar
• Kim TW, Nemergut ME. Preparation of modern anesthesia workstations for malignant hyperthermia susceptible patients. Anesthesiology 2011;114:205-12
   PubMed Web of Science ®Google Scholar
• Dirksen SJH, Larach MG, Rosenberg H, et al. Future directions in malignant hyperthermia and patient care. Anesth Analg 2011;113:1108-19
   PubMedGoogle Scholar
• Birgenheier H, Stoker R, Westenskow D, Orr J. Activated charcoal effectively removes inhaled anesthetics from modern anesthesia machines. Anesth Analg 2011;112:1363-70
   PubMedGoogle Scholar
• Wappler F. Preparation of modern anesthesia workstations for malignant hyperthermia-susceptible patients – when are they really clean? Anesthesiology 2011;115:434-5
   PubMedGoogle Scholar
• Kaufmann A, Kraft B, Michalek-Sauberer A, Weigl LG. Novel ryanodine receptor mutation that may cause malignant hyperthermia. Anesthesiology 2008;109:457-64
   PubMedGoogle Scholar
• Haraki T, Yasuda T, Mukaida K, et al. Mutated p.4894 RYR1 function related to malignant hyperthermia and congenital neuromuscular disease with uniform type 1 fiber (CNMDU1). Anesth Analg 2011;113:1461-7
   PubMedGoogle Scholar
• Schiemann AH, Dürholt EM, Pollock N, Stowell KM. Sequence capture and massively parallel sequencing to detect mutations associated with malignant hyperthermia. Br J Anaesth 2013;110:122-7
   PubMedGoogle Scholar
• Kim JH, Jarvik GP, Browning BL, et al. Exome sequencing reveals novel rare variants in the ryanodine receptor and calcium channel genes in malignant hyperthermia families. Anesthesiology 2013;119:1054-65
   PubMed Web of Science ®Google Scholar
• Litman RS, Rosenberg H. Malignant hyperthermia – update on susceptibility testing. JAMA 2005;293:2918-24
   PubMedGoogle Scholar
• Lerman J. Perioperative management of the paediatric patient with coexisting neuromuscular disease. Br J Anaesth 2011;107(S1):i79-89
   Google Scholar